Halozyme Therapeutics, Inc. (HALO)
Company Info
| ISIN | US40637H1095 |
|---|---|
| CUSIP | 40637H109 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $6.62B |
|---|---|
| EPS (TTM) | $2.58 |
| PE Ratio | 20.26 |
| PEG Ratio | -2.50 |
| Total Revenue (TTM) | $657.27M |
| Gross Profit (TTM) | $501.51M |
| EBITDA (TTM) | $375.07M |
| Year Range | $32.83 - $65.53 |
| Target Price | $61.70 |
| Short % | 10.54% |
| Short Ratio | 7.53 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: HALO vs. APLD, HALO vs. VOO, HALO vs. SPY, HALO vs. ABBV, HALO vs. HIMS, HALO vs. HROW, HALO vs. RXRX
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Halozyme Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Halozyme Therapeutics, Inc. had a return of 42.34% year-to-date (YTD) and 46.96% in the last 12 months. Over the past 10 years, Halozyme Therapeutics, Inc. had an annualized return of 19.20%, outperforming the S&P 500 benchmark which had an annualized return of 11.71%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 42.34% | 22.95% |
| 1 month | -15.57% | 4.39% |
| 6 months | 36.15% | 18.07% |
| 1 year | 46.96% | 37.09% |
| 5 years (annualized) | 28.15% | 14.48% |
| 10 years (annualized) | 19.20% | 11.71% |
Monthly Returns
The table below presents the monthly returns of HALO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -8.41% | 17.61% | 2.19% | -6.34% | 16.25% | 18.22% | 5.54% | 15.54% | -10.35% | 42.34% | |||
| 2023 | -9.02% | -7.30% | -20.42% | -15.87% | 0.93% | 11.22% | 19.10% | -0.93% | -10.24% | -11.34% | 13.99% | -4.27% | -35.04% |
| 2022 | -13.93% | 2.48% | 12.43% | 0.05% | 15.24% | -4.31% | 11.14% | -16.71% | -2.92% | 20.92% | 19.77% | -0.63% | 41.51% |
| 2021 | 11.43% | -4.92% | -7.87% | 19.81% | -17.10% | 9.66% | -8.98% | 1.60% | -3.12% | -6.42% | -13.63% | 22.29% | -5.85% |
| 2020 | 7.05% | 3.11% | -8.07% | 25.93% | 7.13% | 10.47% | 1.42% | 6.64% | -9.36% | 6.54% | 39.64% | 9.23% | 140.89% |
| 2019 | 10.59% | 6.61% | -6.67% | 0.19% | -8.56% | 16.47% | -1.11% | -2.77% | -6.11% | -1.23% | 26.57% | -8.56% | 21.19% |
| 2018 | -7.80% | 5.25% | -0.36% | -3.37% | -2.80% | -8.32% | 7.29% | 1.71% | -1.30% | -14.53% | 6.31% | -11.39% | -27.79% |
| 2017 | 16.90% | 11.00% | 1.09% | 7.56% | -15.35% | 8.64% | -1.09% | 2.60% | 33.51% | 2.07% | 5.30% | 8.52% | 105.06% |
| 2016 | -49.22% | -7.61% | 16.48% | 11.40% | -4.64% | -14.21% | 15.18% | -1.41% | 23.27% | -28.56% | 36.85% | -16.34% | -42.99% |
| 2015 | 47.98% | 5.53% | -5.24% | 4.13% | 16.68% | 30.14% | 3.37% | -25.19% | -23.08% | 16.53% | 13.74% | -2.64% | 79.59% |
| 2014 | 4.47% | -10.03% | -9.83% | -41.36% | 6.04% | 25.06% | -1.42% | -2.46% | -4.21% | 5.71% | -8.73% | 9.91% | -35.62% |
| 2013 | -0.30% | -18.54% | 5.78% | 4.77% | 16.89% | 12.61% | 7.04% | -2.35% | 32.85% | 5.53% | 26.70% | 1.56% | 123.40% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of HALO is 73, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Halozyme Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Halozyme Therapeutics, Inc. was 74.26%, occurring on Dec 4, 2008. Recovery took 795 trading sessions.
The current Halozyme Therapeutics, Inc. drawdown is 18.33%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -74.26% | Jun 6, 2007 | 380 | Dec 4, 2008 | 795 | Feb 1, 2012 | 1175 |
| -71.03% | Jul 23, 2015 | 140 | Feb 10, 2016 | 1069 | May 11, 2020 | 1209 |
| -69.11% | Apr 28, 2004 | 72 | Aug 17, 2004 | 583 | Dec 7, 2006 | 655 |
| -67.79% | Mar 28, 2012 | 89 | Aug 2, 2012 | 322 | Nov 13, 2013 | 411 |
| -59.65% | Jan 24, 2014 | 73 | May 8, 2014 | 263 | May 26, 2015 | 336 |
Volatility
Volatility Chart
The current Halozyme Therapeutics, Inc. volatility is 14.33%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Halozyme Therapeutics, Inc. compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for HALO in comparison to other companies of the Biotechnology industry. Currently, HALO has a PE value of 20.3. This PE ratio falls in the average range for the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for HALO in comparison to other companies of the Biotechnology industry. Currently, HALO has a PEG value of -2.5. This PEG value is considered to be low compared to the rest of the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Halozyme Therapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |